TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Rutgers plans Camden campus nursing school Rutgers University Wednesday announced plans for a School of Nursing at its Camden Campus. feeds.bizjournals.com |
Medical-Device Makers Push for Cuts Medical-device makers have petitioned Senate Finance Chairman Baucus to shave billions of dollars in fees that the industry would face under new health-care legislation. online.barrons.com |
Genzyme: Focusing on Lumizyme Approval Genzyme (GENZ) released its Q3/09 financial results last week, with non-GAAP earnings coming up short of both mine and the markets expectations. Non-GAAP earnings were reported at $0.31 per share, significantly lower than my estimate ($0.39 per share) and the Street’s estimate ($0.44) for non-GAAP earnings. Earnings were reported lower than expected due to remediation efforts (~$24 million charge) and start-up costs at the company’s Allston manufacturing plant, which is where its blockbuster Gaucher disease drug Cerezyme and Fabry disease drug Fabrazyme are produced. Results were also negatively impacted by the recent acquisition of the full rights to oncology drugs Leukine, Fludara and Campath. In particular, Q3/09 marked the first full quarter of sales and marketing personnel attributable to these oncology products. Additionally, Genzyme had to work its way through the management of inventory of these oncology products as there was a significant amount of inventory in the channel at the time of acquisition close.Complete Story » seekingalpha.com |
Pfizer's R&D: Spending vs. Productivity Derek Lowe submits: Courtesy of Bernard Munos, author of the Nature Reviews article that I began blogging about yesterday, comes this note about Pfizer's (PFE) track record with new molecules. His list of Pfizer NMEs since 2000 is Geodon (ziprasidone, 2001), Vfend (voriconazole, 2002), Relpax (eletriptan, 2002), Somavert (pegvisomant, 2003, from Pharmacia & Upjohn), Lyrica (pregabalin, 2004, from Warner Lambert), Sutent (sunitinib, 2006, from Sugen/Pharmacia), Chantix (varenicline, 2006), Selzentry (maraviroc, 2007), and Toviaz (fesoterodine, 2008, from Schwarz Pharma). There are some good drugs on that list, but considering that even just five years ago, the company was claiming that it had 101 NMEs in development, and was going to file 20 NDAs by now, it might seem a bit thin. It might especially seem that way when you look over this graph, also provided by Munos (but not used in his recent article). You can see that Pfizer's R&D spending has nearly tripled since the year 2000, but that cumulative NME line doesn't seem to be bending much. And, as Munos points out, two (and now three) productive research organizations have been taken out along the way to produce these results. It is not, as they say, a pretty picture.Complete Story » seekingalpha.com |
Democrats Focus on Key Elements of Health Bill The White House, with its health-care initiative in doubt, zeroed in on several elements it hoped would survive, including measures to extend the life of Medicare. online.wsj.com |